Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia

Prostate

Volumn 57, Issue 1, 2003, Pages 57-65

  Berger, Andreas P ^a   Kofler, Kurt ^b   Bektic, Jasmin ^b   Rogatsch, Hermann ^b   Steiner, Hannes ^b   Bartsch, Georg ^b   Klocker, Helmut ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b NONE

Author keywords

Benign prostatic hyperplasia; FGF 2; FGF 7; HIF 1; Hypoxia; IL 8; Stromal cells; TGF ; VEGF

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROSTATECTOMY; WESTERN BLOTTING;

ANOXIA; CELL LINE; COLLAGEN TYPE I; COLLAGEN TYPE III; COLLAGEN TYPE IV; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 7; FIBROBLAST GROWTH FACTORS; HUMAN GROWTH HORMONE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-8; LYMPHOKINES; MALE; NUCLEAR PROTEINS; PROSTATE; STROMAL CELLS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0042830775     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10279     Document Type: Article

References (46)

1. Bartsch G, Brüngger A, Schweikert U, Hintner H, Höpfl R, Rohr H. Benign prostatic hyperplasia: Morphometric studies in relation to the pathogenesis. New Dev Biosci 1989;5:34-53.
2. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal end epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992;147:1293-1297.
3. McNeil JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978;15:340-345.
4. Hockel M, Schlenger K, Hockel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525-4528.
5. Hockel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
6. Berra E, Milanini J, Richard DE, Gall ML, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur J. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000;60:1171-1178.
7. Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R. Does the prostatic vascular system contribute to the development of benign prostate hyperplasia? Curr Urol Rep 2002;3:292-296.
8. Harris AL. Hypoxia - A key regulatory factor in tumour growth. Nat Rev Cancer 2001;2:38-47.
9. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors hif 1-alpha and hif 2-alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-421.
10. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor-1 alpha in common human cancersand their metastases. Cancer Res 1999;59:5830-5835.
11. Palmer LA, Semenza GL, Stoler MH, Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 1998;274:212-219.
12. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, Lewis CE. Expression of HIF-1 alpha by human macrophages: Implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002;196:204-212.
13. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613.
14. 2 tension. Am J Physiol 1996;271:1172-1180.
15. Luo JC, Shibuya M. A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1 alpha, 2 alpha, 3 alpha). Oncogene 2001;20:1435-1444.
16. Sheta EA, Trout H, Gildea JJ, Harding MA, Theodorescu D. Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 2001;20:7624-7634.
17. Sherwood E, Fong C, Lee C, Kozlowski J. Basic fibroblast growth factor: A potential mediator of stromal growth in the human prostate. Endocrinology 1992;130:2955-2963.
18. Ittmann M, Mansukhani A. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997;157:351-356.
19. Ropiquet F, Giri D, Lamb DJ, Ittmann M. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol 1999;162:595-599.
20. Story M, Hopp K, Molter M, Meier D. Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. Growth Factors 1994;10:269-280.
21. Siegel Y, Zaidel L, Hanmel I. Morphometric evaluation of benign prostatic hyperplasia. Eur Urol 1990;18:71-73.
22. Kyprianou N, Tu H, Jacobs S. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-675.
23. Shapiro E, Hartanto V, Perlman E, Tang R, Wang B, Lepor H. Morphometric analysis of pediatric and nonhyperplastic glands: Evidence that BPH is not a unique stromal process. Prostate 1997;33:177-182.
24. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997;31:223-233.
25. Cronauer MV, Stadlmann S, Klocker H, Abendstein B, Eder IE, Rogatsch H, Zeimet AG, Marth C, Offner FA. Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells. Am J Pathol 1999;155:1977-1984.
26. Giri D, Ittmann M. Interleukin-8 as a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001;159:139-147.
27. Wartenberg M, Doenmez F, Ling FC, Acker H, Hescheler J, Sauer H. Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryonic bodies grown from pluripotent embryonic stem cells. FASEB J 2001;15:995-1005.
28. Doll J, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Thrombospondin-I, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49:293-305.
29. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura TF, Addeo R, Makuuchi M, Esumi H. Hypoxia respone element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189-197.
30. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology 1990;127:2963-2968.
31. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA. Transforming growth factor-β in benign and malignant prostate. Prostate 1999;39:285-290.
32. Cohen P, Nunn SE, Peehl DM. Transforming growth factor-β induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: Abnormalities in cells cultured from benign prostatic hyperplasia tissues. J Endocrinol 2000;164:215-223.
33. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
34. Peehl DM, Seller RG. Induction of smooth muscle cell phenotypes in cultured human prostatic stromal cells. Exp Cell Res 1997;232:208-215.
35. Peehl DM, Sellers RG. Basic FGF, EGF, and PDGF modify TGF-β-induction of smooth muscle cell phenotype in human prostatic stromal cells. Prostate 1998;35:125-134.
36. Klingler HC, Bretland AJ, Reid SV, Chapple CR, Eaton CL. Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFβ). Prostate 1999;41:110-120.
37. Chung LWK, Cunha GR. Stromal-epithelial interactions. 2. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 1983;4:503-511.
38. Inagaki Y, Truter S, Ramirez F. Transforming growth factor-β stimulates alpha 2(1) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem 1994;269:14828-14833.
39. Fukabori Y, Nakano K, Ohyama A, Yamanaka H. Stimulative effect of transforming growth factor-beta on collagen synthesis by human prostatic stromal cells in vitro. Int J Urol 1997;4:597-602.
40. Bartsch G, Brüngger A, Schweikert U, Hintner H, Höpfl R, Rohr HP. Benign prostatic hyperplasia: A stromal disease. Urologe A 1989;28:321-328.
41. Richier JC, Kaplan EP, Chermansky CJ, Ewalt DH, Lin VK, McConnell JD. Analysis of type III collagen mRNA expression in human benign prostatic hyperplasia. J Urol 1995;153:344A.
42. Mariotti A, Donovan MP, Mawhinney M. Collagen and cellular proliferation in spontaneous canine benign prostatic hypertrophy. J Urol 1982;127:795-797.
43. Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. Br J Urol 2000;85:70-73.
44. Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC. The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. J Urol 2001;165:2075-2081.
45. Walsh K, Sriprasad D, Hopster D, Codd J, Mulvin D. Distribution of vascular endothelial growth factor (VEGF) in prostate disease. Prost Cancer Prost Diseases 2002;5:119-122.
46. Tuxhorn JA, McAlhany SJ, Yang F, Dang TD, Rowley DR. Inhibition of transforming growth factor-β activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002;62:6021-6025.